Cargando…

Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

AIMS/HYPOTHESIS: Glucagon-like peptide-1 (GLP-1) analogues reduce the risk of macrovascular disease in diabetes; however, little is known about their microvascular effects. This research examined the microvascular actions of the GLP-1 analogues liraglutide and exenatide in individuals with and witho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aung, Myo Myo, Slade, Kate, Freeman, Leighton A. R., Kos, Katarina, Whatmore, Jacqueline L., Shore, Angela C., Gooding, Kim M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677680/ https://www.ncbi.nlm.nih.gov/pubmed/31203378 http://dx.doi.org/10.1007/s00125-019-4918-x

Ejemplares similares

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
por: Pinkney, Jonathan, et al.
Publicado: (2010)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
por: Lv, Jing, et al.
Publicado: (2014)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

The effect of the GLP‐1 analogue Exenatide on functional connectivity within an NTS‐based network in women with and without obesity
por: Coveleskie, K., et al.
Publicado: (2017)

GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling
por: Chang, Ching-Chi, et al.
Publicado: (2018)

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model
por: Parthsarathy, Vadivel, et al.
Publicado: (2013)

Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
por: Aung, Myo Nyein, et al.
Publicado: (2010)

Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
por: Voukali, Maria, et al.
Publicado: (2014)

SAT-635 Results of a Preclinical Pilot Study Evaluating 24-Hour Subcutaneous Infusion of the GLP-1 Analogue Liraglutide Delivered via the H-Patch Wearable Device
por: Barnes, Jessica W, et al.
Publicado: (2020)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
por: Barnett, A H
Publicado: (2012)

The effects of a GLP-1 analogue liraglutide on reward value and the learned inhibition of appetitive behavior in male and female rats
por: Jones, Sabrina, et al.
Publicado: (2018)

The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp
por: Wu, Hui, et al.
Publicado: (2014)

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
por: Femminella, Grazia Daniela, et al.
Publicado: (2019)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
por: Robinson, Louise E, et al.
Publicado: (2013)

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide
por: DeKoven, Mitch, et al.
Publicado: (2014)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1 Signaling Pathway
por: Zhu, Tao, et al.
Publicado: (2018)

Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
por: Femminella, Grazia Daniela, et al.
Publicado: (2020)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
por: Shi, Shaomin, et al.
Publicado: (2023)

Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages
por: Bułdak, Łukasz, et al.
Publicado: (2015)

Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
por: Cacciatori, Vittorio, et al.
Publicado: (2017)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
por: Fujishima, Yuya, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
por: Wronka, Magdalena, et al.
Publicado: (2023)

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
por: Bode, B W, et al.
Publicado: (2010)

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
por: Inoue, Kana, et al.
Publicado: (2014)

The effects of GLP-1 analogues on pre-diabetes of the children
por: Zhou, Qing-Xia, et al.
Publicado: (2017)

A case of large atrial myxoma presenting as an acute stroke
por: Iyer, Praneet, et al.
Publicado: (2016)

Development of near real-time wireless image sequence streaming cloud using Apache Kafka for road traffic monitoring application
por: Htut, Aung Myo, et al.
Publicado: (2022)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
por: Vandemark, Collin, et al.
Publicado: (2023)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
por: McDonell, Amanda L, et al.
Publicado: (2015)

Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
por: de Mesquita, Fernanda Cristina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pio6pv4hd9dkq9hjl3vrtrhm40